Healthcare

Rothschild & Co Redburn (LSE:RKT) has issued a‘Buy’rating on Reckitt Benckiser Group plc (LSE:RKT), setting a target price of GBP 6,700, reflecting an upside potential of 13.75% from current levels. The rating follows the company’s announcement of its Q3 2025 performance, highlighting sustained growth …

MedPal AI Plc (AIM:MPAL) has officially opened a new 24/7 AI-powered distribution centre at Ecotech Business Park, Swaffham. The development follows the acquisition of key assets from Universal Pharmacy Limited, including a Distance Selling Pharmacy (DSP) licence and a warehouse unit. With the GPhC …

GSK plc (LSE:GSK) announced positive Phase III data from its clinical programme for a next-generation version of its metered dose inhaler (MDI), Ventolin (salbutamol). The study demonstrated that the salbutamol MDI containing the innovative low-carbon propellant HFA-152a has therapeutic equivalence and a comparable safety …

AstraZeneca (LSE:AZN) is a global, research-driven biopharmaceutical company dedicated to the discovery, development, and marketing of innovative prescription medicines across Oncology, Rare Diseases, and BioPharmaceuticals. Headquartered in Cambridge, UK, the company’s therapies improve the lives of patients in more than 125 countries.

Aptamer Group plc(LSE:APTA) Group produces Optimer® binders, molecules that function similarly to antibodies by binding to specific targets in the body. These binders are applied in therapeutics, diagnostics, and research tools, offering advantages such as high stability, consistent performance, and lower costs compared with …

Renalytix plc (LSE:RENX) (OTCQB:RNLXY), a precision medicine company focused on early-stage risk assessment in chronic kidney disease (CKD), has announced its intention to raise a minimum of £4.0 million in gross proceeds. The capital will be secured through a placing, a subscription of new …

Haleon Plc (LSE:HLN), the world’s largest pure-play consumer health company, has received a vote of confidence fromJefferies, with analystDavid H. Hayesreaffirming aBuyrating on the stock. Hayes set a price target ofAUD 9.00, representing a potential upside of more than20%from the current level ofAUD 7.47.